Amgen taps Hummingbird’s tech for epitope-based antibody selection
Hummingbird’s method of identifying an antigen’s binding epitopes and screening antibodies has garnered the Singaporean company a new partner in Amgen. The companies revealed Monday that they will discover antibodies against undisclosed targets using Hummingbird’s Rational Antibody Discovery platform.
Amgen Inc. (NASDAQ:AMGN) will provide Hummingbird with two targets for which Hummingbird Bioscience Pte. Ltd. will identify binding epitopes and select antibodies against the epitopes, and may add up to 10 additional targets over a six-year period. Amgen has an exclusive option to license rights to the resulting antibodies. Hummingbird will receive undisclosed upfront and research payments and is eligible for up to $100 million per project in development and commercial milestones should Amgen exercise an option. ...